^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SSTR5 (Somatostatin Receptor 5)

    i
    Other names: SSTR5, Somatostatin Receptor 5, Somatostatin Receptor Type 5, SS-5-R, Somatostatin Receptor Subtype 5, SSTR5, SS5-R, SS5R
    2ms
    Genomic analysis of PLNTY-like tumor progression into epithelioid glioblastoma: a case report. (PubMed, Acta Neuropathol Commun)
    Notably, only a limited set of genetic alterations was associated with malignant transformation beyond genome duplication, the CDKN2A/B inactivation representing the best-known oncogenic driver for malignant transformation. These findings suggest that genomic profiling may be a valuable tool for the diagnosis and prognostic assessment of low-grade neuroepithelial lesions.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CD34 (CD34 molecule) • SSTR5 (Somatostatin Receptor 5)
    |
    BRAF V600E • BRAF V600 • CDKN2A deletion • IDH wild-type
    2ms
    Structural insights into nonpeptide antagonist inhibition of somatostatin receptor subtype 5. (PubMed, Proc Natl Acad Sci U S A)
    Furthermore, we delineate rational avenues for molecular optimization to enhance therapeutic index and mitigate off-target liabilities. These findings, complementing our previous agonist-bound structures, establish a comprehensive structural foundation for developing improved nonpeptidic SSTR5 antagonists with potential therapeutic applications for type 2 diabetes and related endocrine disorders.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR5 (Somatostatin Receptor 5)
    3ms
    Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH-PitNETs, Mammosomatotrophs and Mixed Tumors. (PubMed, J Clin Endocrinol Metab)
    These findings highlight the heterogeneity within GH&PRL-PitNETs, including silent PRL-positive GH PitNETs. Our data suggest mixed-SL tumors may be less responsive to somatostatin receptor ligands, emphasizing the need for tailored strategies based on tumor subtype and receptor profile.
    Journal
    |
    CDH1 (Cadherin 1) • SSTR (Somatostatin Receptor) • IGF1 (Insulin-like growth factor 1) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5) • PRL (Prolactin)
    3ms
    Somatostatin receptors 3 and 5 potentiate cholinergic-nerve-mediated contraction in human bronchus. (PubMed, Front Pharmacol)
    The present study provided new data on the location of SSTR in the human lung: notably, all types of receptor were found in the parasympathetic nerve ganglia of the bronchial wall. We suggest that the activation of prejunctional SSTR3 and SSTR5 receptors potentiates cholinergic-nerve-mediated contraction induced by EFS in human bronchi.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
    3ms
    Immunohistochemical analysis of filamin a expression in acromegaly and its correlation with tumor characteristics and treatment response. (PubMed, Sci Rep)
    In conclusion, our results suggest that FLNA may be associated with tumor invasiveness in GH-secreting pituitary tumors. While data on Pasireotide-treated patients are exploratory, further studies are needed to assess FLNA's potential as a treatment response marker in acromegaly.
    Journal
    |
    CDH1 (Cadherin 1) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5) • FLNA (Filamin A)
    |
    Signifor (pasireotide)
    5ms
    Hypermethylated Long Non-Coding RNA Genes KCNK15-AS1, MAGI2-AS3, and SSTR5-AS1 in Ovarian Cancer and Their Diagnostic Potential. (PubMed, Bull Exp Biol Med)
    The developed marker panel may be of interest for the molecular assessment of at-risk patients when determining a preliminary diagnosis. However, the method requires validation on a larger, more representative sample set.
    Journal
    |
    SSTR5 (Somatostatin Receptor 5) • SSTR5-AS1 (SSTR5 Antisense RNA 1) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    5ms
    World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC. (PubMed, Eur J Endocrinol)
    The MS-18 cell line is the first patient-derived cell line with a transitional phenotype between differentiated NET and dedifferentiated NEC, showing strong expression of SSTR2 and CXCR4 and absence of driver mutations in key NET-/NEC-associated genes. It offers a unique platform for preclinical evaluation of targeted therapies.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ATRX (ATRX Chromatin Remodeler) • CDH1 (Cadherin 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5) • DAXX (Death-domain associated protein) • SYP (Synaptophysin)
    |
    TP53 mutation • PTEN mutation
    |
    etoposide IV
    6ms
    Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study. (PubMed, Cancer)
    This study provides real-world data on 600 GEP-NENs in Taiwan and identifies age, Eastern Cooperative Oncology Group performance status score, tumor grade, tumor stage, and SSTR2 expression as prognostic factors for the survival of GEP-NENs.
    Clinical data • Journal
    |
    SSTR2 (Somatostatin Receptor 2) • CDX2 (Caudal Type Homeobox 2) • SSTR5 (Somatostatin Receptor 5) • PDX1 (Pancreatic And Duodenal Homeobox 1) • NEUROD1 (Neuronal Differentiation 1)
    7ms
    The mechanism of lncRNA SSTR5-AS1 promoting ferroptosis resistance and immune escape in ovarian cancer cells by recruiting STAT3 to regulate SLC7A11 expression. (PubMed, Cancer Genet)
    SSTR5-AS1 promoted SLC7A11 transcription and expression by recruiting STAT3, thereby promoting ferroptosis resistance and immune escape of OC cells.
    Journal
    |
    CD8 (cluster of differentiation 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • SLC7A11 (Solute Carrier Family 7 Member 11) • SSTR5 (Somatostatin Receptor 5) • SSTR5-AS1 (SSTR5 Antisense RNA 1)
    |
    erastin
    7ms
    A Rare Case of Retroperitoneal Teratoma Mimicking Paraganglioma on Multimodality Imaging. (PubMed, Clin Nucl Med)
    However, postoperative pathology confirmed a teratoma containing thyroid tissue with positive somatostatin receptor (SSTR) 2 and SSTR 5 expression, which may explain the false-positive uptake on 68Ga-DOTATATE. This case may provide a critical differential diagnostic consideration in retroperitoneal masses with high 68Ga-DOTATATE uptake.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR5 (Somatostatin Receptor 5)
    |
    SSTR positive
    7ms
    Dopamine receptor expression predicts cabergoline response in persistent somatotroph adenoma. (PubMed, Pituitary)
    D2 receptor profiling of growth hormone secreting pituitary tumors and post-operative IGF-1 level at 3 months are helpful to predict response to medical treatment with cabergoline.
    Journal
    |
    SSTR (Somatostatin Receptor) • IGF1 (Insulin-like growth factor 1) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)
    8ms
    Comparison of radiolabeled somatostatin analogs (DOTATATE, DOTANOC, and DOTATOC) in somatostatin receptor (SSTR) imaging for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a narrative literature review. (PubMed, Ann Nucl Med)
    PET/CT scans are recommended over SPECT/CT for GEP-NEN diagnosis due to their higher accuracy. Enhancements in diagnostic performance may be achieved by combining SSTR tracers with radionuclides like 64Cu and 18F, using somatostatin antagonists as tracers, or employing dual-tracer protocols with 18F-FDG.
    Review • Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2) • SSTR5 (Somatostatin Receptor 5)